European Studies Help Plan A Path Forward For Value Added Medicines
Six value added medicines case studies across six European countries are featured in the latest IQVIA report for Medicines for Europe. Each of them, according to the association’s sector chair Arun Narayan, helps point to a way forward for value added medicines in Europe.
You may also be interested in...
Belgium’s recent royal decree on pharmaceutical reimbursement represents “three significant steps forward for the generic medicines sector”, according to local off-patent industry association FeBelGen. As well as simplifying reimbursement, the association points out, the decree also sets out a reimbursement pathway for value-added medicines as well as removing certain packaging requirements.
A CJEU advocate general has backed a European Commission fine of almost €94m imposed on Lundbeck over “pay for delay” deals struck with four generics firms over citalopram.
Mylan and Lupin have revealed when they expect to launch their etanercept biosimilar, Nepexto, in Europe after receiving formal European Commission approval.